Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT02273635 : Efficacy, Safety and Tolerability of Andrographolides Versus Placebo in Patients With Progressive Forms of MS
PhasePhase 1/Phase 2
AgesMin: 18 Years Max: 70 Years
Eligibility
Inclusion Criteria:

- Signed Informed Consent previous to the initiation of the study before any
evaluation.

- Men and women > 18 years of age with Minimental > 24.

- Patients with diagnosis of secondary progressive MS without relapses or primary
progressive MS according to the criteria of McDonald 2010.

Exclusion Criteria:

- Relapsing-remitting MS

- Current Immunomodulatory or immunosuppressive therapy

- Uncontrolled systemic diseases not controlled or treated with immunotherapy (i.e
Rheumatoid Arthritis, Lupus Erythematosus).

- Pregnant women
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT02273635      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740